值得一提的是，POLARIS-1研究的最新进展也将在即将召开的2025年美国血液学会( American Society of Hematology，ASH)年会上亮相，这是该研究数据的首次公布。目前已披露的摘要数据显示：在耐立克®联合低强度化疗治疗的初治Ph+ ALL患者中，三周期分子MRD(微小残留病)阴性率、分子MRD阴性CR(完全缓解)率均可达65%左右，较国外同类产品在同样条件下的疗效明显提升；即使是对一些高危亚型如携带IKZF1plus基因变异的患者也达到了很好的疗效。同时，该联合方案的安全性表现优异，副作用发生率低且可控制。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.